Search clinical trials for: Onureg Venetoclax

Total 603 results

Groupe Francophone des Myelodysplasies
Bristol-Myers Squibb; AbbVie

Recruiting

Oral Azacitidine Combined With Venetoclax in Previously Untreated Higher-risk Myelodysplastic Syndromes

Untreated Myelodysplastic Syndrome

France
Celgene
AbbVie

Completed

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML) (OMNIVERSE)

Leukemia, Myeloid, Acute

United States, Australia
University of Colorado, Denver
The Leukemia and Lymphoma Society

Not yet recruiting

Cladribine Venetoclax in Monocytic AML

Acute Myeloid Leukemia

United States
Virginia Commonwealth University
AbbVie

Withdrawn

Venetoclax and Irinotecan in Relapsed/Refractory SCLC

Relapsed Small Cell Lung Cancer | Refractory Small Cell Lung Carcinoma
PrECOG, LLC.
Genentech, Inc.

Completed

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403)

Follicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High Grade

United States
University of Colorado, Denver

Not yet recruiting

Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia

Leukemia | Myeloid Leukemia | Monocytic Leukemia

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic Lymphoma Group

Active, not recruiting

CLL Induction Treatment With Venetoclax and Ibrutinib, Followed by Ibrutinib and Obinutuzumab in Patients With MRD.

CLL

Netherlands, Denmark
University of Maryland, Baltimore

Active, not recruiting

Pegcrisantaspase in Combination With Venetoclax for Treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML)

Relapsed or Refractory Acute Myeloid Leukemia

United States
Yale University

Completed

A Study of ABT-199 (Venetoclax) for Cutaneous T Cell Lymphoma (CTCL)

CTCL

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome

Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Recurrent Myelodysplastic Syndrome | Refractory Myelodysplastic Syndrome | Therapy-Related Myelodysplastic Syndrome

United States
BioSight Ltd.

Recruiting

A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML

AML, Adult

United States
M.D. Anderson Cancer Center

Recruiting

Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting

Acute Myeloid Leukemia | Therapy-Related Acute Myeloid Leukemia | Acute Bilineal Leukemia | Acute Biphenotypic Leukemia | T Acute Lymphoblastic Leukemia | Mixed Phenotype Acute Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Prospective and Retrospective Observational Evaluation of Real World Outcome of Unfit AML Patients Treated With the Combination Venetoclax Plus Hypomethylating Agents, Under the Italian Law No.648/96

Acute Myeloid Leukemia

Italy
Aptose Biosciences Inc.

Recruiting

Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (APTIVATE)

Relapsed or Refractory Acute Myeloid Leukemia

United States, Germany, Spain, Korea, Republic of, Australia, New Zealand
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
The Lymphoma Academic Research Organisation
Institute of Cancer Research, United Kingdom

Recruiting

Study of Ibrutinib + CD20 Antibody and Venetoclax in Patients With Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

France, United Kingdom, Belgium
National Heart, Lung, and Blood Institute (NHLBI)

Recruiting

Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
Institute of Hematology & Blood Diseases Hospital

Not yet recruiting

Intensive Therapy Combined With Venetoclax for Adult Acute Myeloid Leukemia

Acute Myeloid Leukemia
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
Montefiore Medical Center
M.D. Anderson Cancer Center; Flamingo Therapeutics NV

Recruiting

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

Acute Myeloid Leukemia | Myelodysplastic Syndromes | AML/MDS

United States
Hikma Pharmaceuticals LLC

Not yet recruiting

Bioequivalence of Azacitidine 300 mg Film-Coated Tablets in Adult Patients With Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia
Pharmacyclics LLC.
Janssen Research & Development, LLC

Active, not recruiting

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Mantle-Cell Lymphoma

France, Canada, Spain, United States, Hungary, Korea, Republic of, Greece, Australia, Netherlands, Belgium, United Kingdom, Czechia, Germany, Poland, Italy, Turkey, Ukraine
Brian Jonas
National Cancer Institute (NCI); GlycoMimetics Incorporated

Recruiting

Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
French Innovative Leukemia Organisation
AbbVie; Janssen-Cilag Ltd.

Active, not recruiting

Evaluation of Risk-Adapted and MRD-Driven Strategy for Untreated Fit Patients With Intermediate Risk Chronic Lymphocytic Leukemia (ERADIC)

Intermediate Risk Chronic Lymphocytic Leukemia | Fit Patients | Risk-Adapted and MRD-Driven Strategy

France
Shanghai Jiao Tong University School of Medicine
Shanghai Clinical Research Center

Recruiting

Treatment of Chidamide and Venetoclax for Retinoic Acid and Arsenic Resistant Acute Promyelocytic Leukemia

APL

China
Memorial Sloan Kettering Cancer Center
Adaptive Biotechnologies

Recruiting

Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Shanghai Jiao Tong University School of Medicine

Not yet recruiting

A Phase 2 Study of Venetoclax in Combination With Low-dose HHT, G-CSF, and AZA as First-line Treatment for Newly Diagnosed Elderly AML Patients Unfit for Intensive Chemotherapy

Leukemia, Myeloid, Acute
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia

United States
The First Affiliated Hospital of Soochow University

Enrolling by invitation

Clinical Study of Venetoclax Combined With Azacytiside in the Treatment of Myelodysplastic/Myeloproliferative Neoplasms in Adults

Myelodysplastic/Myeloproliferative Neoplasms | Adult

China
Xianmin Song, MD

Recruiting

Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies

Leukemia, Myeloid, Acute | Myeloid Malignancy | MDS | Hematopoietic Stem Cell Transplantation

China
Stichting Hemato-Oncologie voor Volwassenen Nederland

Recruiting

REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL)

CLL/SLL

Netherlands, Belgium, Denmark
M.D. Anderson Cancer Center

Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Hematopoietic and Lymphoid System Neoplasm | Myeloproliferative Neoplasm

United States
University of Ulm
AbbVie; Roche Pharma AG; Janssen-Cilag Ltd.; German CLL Study Group

Completed

Trial of Ibrutinib Plus Venetoclax Plus Obinutuzumab in Patients With CLL (CLL2-GiVe)

Leukemia, Lymphocytic, Chronic

Germany
Brian Jonas
National Cancer Institute (NCI); AbbVie

Recruiting

Azacitidine or Decitabine With Venetoclax for Acute Myeloid Leukemia With Prior Hypomethylating Agent Failure

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia

United States
Technische Universität Dresden
AbbVie

Active, not recruiting

Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX) (RELAX)

Relapsed Adult AML | Refractory AML

Germany
Institut de Recherches Internationales Servier
ADIR, a Servier Group company

Completed

Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.

Acute Myeloid Leukaemia

France, United States, Australia
ZePing Zhou
Guizhou Provincial People's Hospital; Second Xiangya Hospital of Central South... and other collaborators

Recruiting

A Study on the Efficacy and Safety of Venetoclax Combined With HAA Regimen in Newly Diagnosed Young AML.

Acute Myeloid Leukemia | Venetoclax

China
Universitätsklinikum Hamburg-Eppendorf

Recruiting

Combination Treatment of Belantamab Mafodotin and Venetoclax in Treatment of Relapsed and Refractory t(11;14) Multiple Myeloma (BELI(E)VE)

Multiple Myeloma | Multiple Myeloma in Relapse

Germany
Bnai Zion Medical Center
Tel-Aviv Sourasky Medical Center

Recruiting

A Study to Evaluate the Efficacy and Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Patients With Richter's Syndrome;

Richter's Syndrome

Israel
Peking University People's Hospital

Recruiting

Clinical Study of Venetoclax Combined With CAG in the Treatment of Refractory/Relapsed Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
AbbVie
Genentech, Inc.

Completed

A Phase 2 Study of ABT-199 in Subjects With Acute Myelogenous Leukemia (AML)

Acute Myeloid Leukemia | AML | Acute Myelogenous Leukemia
Craig Portell, MD
AbbVie

Completed

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL

Lymphoma, Mantle-Cell | Recurrent Lymphoma, Mantle-Cell

United States
Novartis Pharmaceuticals

Completed

Study of the Impact of Indacaterol (Onbrez®) on the Individual Lives and Health Status of Patients With COPD (INHALE)

Chronic Obstructive Pulmonary Disease

United Kingdom
National Research Center for Hematology, Russia

Recruiting

MRD-associated Non-intensive But Non-interruptive Treatment of Ph-negative Acute Lymphoblastic Leukemia Adult Patients

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Russian Federation
Uma Borate

Recruiting

Venetoclax and Azacitidine for Treatment of Therapy Related or Secondary Myelodysplastic Syndrome

Therapy-Related Myelodysplastic Syndrome | Secondary Myelodysplastic Syndrome

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Acute Myeloid Leukemia | Polycythemia Vera | Essential Thrombocythemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome | Myeloproliferative Neoplasm | Chronic Neutrophilic Leukemia | Myeloid Neoplasm | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Myelodysplastic/Myeloproliferative... and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Not yet recruiting

Testing the Use of Combination Therapy in Patients With Persistent Low Level Acute Myeloid Leukemia (AML) Following Initial Treatment (ERASE)

Leukemia, Myeloid, Acute
Dalian Medical University

Not yet recruiting

Linperlisib Plus Obinutuzumab and Venetoclax for Relapsed and Refractory Blastoid Variant of Mantle Cell Lymphoma.

Mantle Cell Lymphoma

China
Poitiers University Hospital

Recruiting

Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

Waldenstrom's Macroglobulinaemia Refractory

France
National Taiwan University Hospital

Recruiting

Pharmacokinetics of Venetoclax in Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia

Taiwan

Search clinical trials for: Onureg Venetoclax

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hong Kong

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations